Table 2 Procedure-related characteristics of the studied patients
Variables | Ticagrelor 90 mg (n = 171) | Ticagrelor 60 mg (n = 178) | Clopidogrel 75 mg (n = 176) | P-value |
|---|---|---|---|---|
Site of access | ||||
Radial | 58 (33.9%) | 52 (29.2%) | 54 (30.7%) | 0.627 |
Femoral | 23 (13.5%) | 41 (23.0%) | 35 (19.9%) | 0.067 |
Radial and Femoral | 90 (52.6%) | 85 (47.8%) | 87 (49.4%) | 0.657 |
Total amount of conrrast (ml) | 233.8 ± 102.0 | 228.3 ± 98.6 | 215.8 ± 94.6 | 0.327 |
Total time of procedure (min) | 123.6 ± 55.9 | 119.8.1 ± 57.5 | 128.4 ± 64.3 | 0.621 |
LAD occlusion, n (%) | 60 (35.1%) | 55 (30.9%) | 58 (33.0%) | 0.716 |
LCX occlusion, n (%) | 32 (18.7%) | 29 (16.3%) | 28 (15.9%) | 0.766 |
RCA occlusion, n (%) | 89 (52.0%) | 96 (53.9%) | 92 (52.3%) | 0.939 |
Occlusion lesion length, mm | 58.4 ± 26.3 | 55.9 ± 24.6 | 56.6 ± 25.4 | 0.748 |
Retrograde filling > grade 2 | 85 (49.7%) | 82 (46.1%) | 81 (46.0%) | 0.730 |
Reverse wire technique | 44 (25.7%) | 51 (28.7%) | 48 (27.3%) | 0.827 |
IABP, n(%) | 12 (7.0%) | 9 (5.1%) | 11 (6.3%) | 0.743 |
IVUS, n(%) | 34 (19.9%) | 38 (21.3%) | 36 (20.5%) | 0.953 |
Number of stents per patient | 2.8 ± 1.9 | 2.6 ± 1.8 | 2.7 ± 2.0 | 0.568 |
Stent length (mean, mm) | 65.9 ± 26.3 | 66.4 ± 29.5 | 67.2 ± 31.4 | 0.382 |
TIMI III flow after PCI | 152 (88.9%) | 162 (91.0%) | 158 (89.8%) | 0.814 |
Glycoprotein IIb/IIIa receptor inhibitor, n(%) | 46 (26.9%) | 55 (30.9%) | 52 (29.5%) | 0.716 |
LMWH, (%) | 50 (29.2%) | 48 (27.0%) | 56 (31.8%) | 0.611 |